1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK) — Johann S. de Bono (2023) | RDL Network
1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
J.S. de Bono, Carole Hélissey, K. Fizazi, J.P. Maroto Rey, Guilhem Roubaud, Emmanuel S. Antonarakis, Shahneen Sandhu, N.D. Shore, R. Ratta, Begoña P. Valderrama, Christof Vulsteke, Lisa Schäfer, G. Marr, Eric Y. Stutheit-Zhao, Alex Ward, J.M. Piulats Rodriguez
Carmel Pezaro, Aurelius Omlin, Deborah Mukherji, Diletta Bianchini, Shahneen Sandhu, Amy Mulick, Gal Maier, David Olmos, Emilda Thompson, Gerhardt Attard, Johann S. de Bono
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Mathias Bressel, Rhonda Huynh, Patricia Banks, Roslyn Wallace, Anis Hamid, Andrisha Jade Inderjeeth, Ben Tran, Arun Azad, Ramin Alipour, Grace Kong, Aravind Ravi Kumar, Javad Saghebi, Scott Williams, Timothy Akhurst, Rodney J. Hicks, Michael S. Hofman
Shahneen Sandhu, John Violet, Justin Ferdinandus, Sue-Ping Thang, Amir Iravani, Christina Guo, Grace Kong, Aravind Ravi Kumar, Timothy Akhurst, Alexis Beaulieu, Declan G. Murphy, Jennifer Mooi, Ben Tran, Guy C. Toner, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Weickhardt, S.T. Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Hendrick Tan, Ian Kirkwood, Shahneen Sandhu, Amy Nguyen, Craig Gedye, Natalie Rutherford, Michael S. Hofman, Andrew Martin, Martin R. Stockler, Ian D. Davis
Discussion(0)
No comments yet. Be the first to comment.